Journal of reproductive immunology · 2026
Poriferast-5-en-3β-ol improves pelvic inflammatory disease via reducing GADD45A-induced inflammation.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Baoqin, Wang Qing, Yu Junjie, Dong Huijing, Jin Zhe
Аннотация
BACKGROUND: Pelvic inflammatory disease (PID), often triggered by pathogens like Chlamydia, is a major cause of female infertility. This study investigated molecular mechanisms in PID and the therapeutic potential of DanZhiYin (DZY) and its components.
METHODS: Bioinformatic analysis of dataset GSE110106 identified differentially expressed genes in PID, validated clinically. A Chlamydia infection model in OE-E6/E7 cells was used. siRNA knockdown and overexpression revealed GADD45A's role. Anti-inflammatory effects of DZY, Salvia miltiorrhiza, and Poriferast-5-en-3β-ol were tested via quantitative reverse transcription polymerase Chain Reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA). Molecular dynamics and rescue experiments clarified the mechanism, and a PID mouse model assessed efficacy.
RESULTS: MAPK signaling was upregulated in PID. GADD45A was identified as a key diagnostic marker, with an area under the curve (AUC) of 0.747. Chlamydia infection increased GADD45A and cytokines; its silencing reduced inflammation, while overexpression exacerbated it. DZY, Salvia miltiorrhiza, and Poriferast-5-en-3β-ol inhibited inflammation dose-dependently. Poriferast-5-en-3β-ol directly binds to GADD45A, thereby suppressing the production of IL-1β and TNF-α by inhibiting p38 MAPK and its phosphorylated form (p-p38). In vivo, all treatments reduced bacterial load and inflammation, with DZY being most effective.
CONCLUSION: GADD45A is a central inflammatory regulator in PID. DZY and Poriferast-5-en-3β-ol attenuate inflammation by targeting GADD45A, providing new mechanistic and therapeutic insights for PID.
METHODS: Bioinformatic analysis of dataset GSE110106 identified differentially expressed genes in PID, validated clinically. A Chlamydia infection model in OE-E6/E7 cells was used. siRNA knockdown and overexpression revealed GADD45A's role. Anti-inflammatory effects of DZY, Salvia miltiorrhiza, and Poriferast-5-en-3β-ol were tested via quantitative reverse transcription polymerase Chain Reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA). Molecular dynamics and rescue experiments clarified the mechanism, and a PID mouse model assessed efficacy.
RESULTS: MAPK signaling was upregulated in PID. GADD45A was identified as a key diagnostic marker, with an area under the curve (AUC) of 0.747. Chlamydia infection increased GADD45A and cytokines; its silencing reduced inflammation, while overexpression exacerbated it. DZY, Salvia miltiorrhiza, and Poriferast-5-en-3β-ol inhibited inflammation dose-dependently. Poriferast-5-en-3β-ol directly binds to GADD45A, thereby suppressing the production of IL-1β and TNF-α by inhibiting p38 MAPK and its phosphorylated form (p-p38). In vivo, all treatments reduced bacterial load and inflammation, with DZY being most effective.
CONCLUSION: GADD45A is a central inflammatory regulator in PID. DZY and Poriferast-5-en-3β-ol attenuate inflammation by targeting GADD45A, providing new mechanistic and therapeutic insights for PID.